Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non-small cell lung cancer (NSCLC). We optimized and validated an IHC assay for LKB1 (clone L...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-06, Vol.21 (12), p.2851-2860
Hauptverfasser:	Calles, Antonio, Sholl, Lynette M, Rodig, Scott J, Pelton, Ashley K, Hornick, Jason L, Butaney, Mohit, Lydon, Christine, Dahlberg, Suzanne E, Oxnard, Geoffrey R, Jackman, David M, Jänne, Pasi A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Aged Aged, 80 and over Biomarkers Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Disease Progression Female Genotype High-Throughput Nucleotide Sequencing Humans Immunohistochemistry Kaplan-Meier Estimate Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Mutation Neoplasm Metastasis Neoplasm Staging Prognosis Protein-Serine-Threonine Kinases - metabolism Proto-Oncogene Proteins p21(ras) - genetics Retrospective Studies Risk Factors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!